CTOs on the Move

XyloCor

www.xylocor.com

 
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company`s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Alexander Gaidamaka
 Senior Vice President of Technology, Manufacturing and Quality Profile

Funding

XyloCor raised $17M on 12/06/2018
XyloCor raised $22.6M on 03/22/2021

Similar Companies

BIOMERIX

BIOMERIX is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cancer Genetic Consultants

Cancer Genetic Consultants is a Leawood, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Agensys

Agensys is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paradigm Diagnostics

Paradigm is a medical diagnostics company serving physicians and patients worldwide.

Kurome Therapeutics

Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.